Please assess the completion status of the following clinical trial:

Trial Title: A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have completed the 12-week study D3820C00004 through Visit 8.~* Provision of written informed consent prior to any study-specific procedures.~* Men and women who were between the ages of \>18 and \<85 years at the time of the screening visit for study D3820C00004.~* Continuing to receive a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies.~* Willingness to continue abstinence from all laxatives and other bowel regimens including prune juice and herbal products throughout this additional 12-week treatment period, and to use only bisacodyl as rescue medication if a bowel movement (BM) has not occurred within at least 72 hours of the last recorded BM.~Exclusion Criteria:~* Patients receiving opioid regimen for treatment of pain related to cancer.~* History of cancer within 5 years from the screening visit of study D3820C00004 with the exception of basal cell cancer and squamous cell skin cancer.~* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.~* Other issues related to the gastrointestinal tract that could impose risk to the patient.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- NKTR-118 12.5mg (Type: EXPERIMENTAL): None
- NKTR-118 25mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).